Contact hours available until 2/28/17.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Planning Committee Disclosures:
Christine Bradway, PhD, RN, CRNP: Consultant/Presenter Bureau: Direct Supply Inc. and Advisory Board: Astelles

Cheryl A. LeCroy, MSN, RN: Consultant: Allergan

Speaker Disclosures:
There are no disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
This session is jointly provided by SUNA and Plexus Communication.

Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.

Objectives:

Compare the benefits and risks associated with new systemic agents for the treatment castrate resistant prostate cancer including immunotherapy, “secondary” hormonal agents, chemotherapy and radiopharmaceuticals.
Assess current treatment guidelines regarding appropriate sequencing of new therapeutic approached for the treatment of mCRPC
Appraise individual patient disease characteristics: recognize and manage disease and treatment related complications associated with mCRCP
Formulate appropriate care plans and provide counsel for patients and their families

Neil Shore

Appearances